Antares Pharma Reports Recent Developments and Third Quarter 2008 Financial Results
Highlights -- Appointed Paul K. Wotton, Ph.D., as President and Chief Executive Officer -- Appointed Leonard S. Jacob, M.D., Ph.D., as Chairman of the Board of Directors -- Revenues from product sales and royalty income increased to $1.12 million in the third quarter, an increase of over 10% compared to the same period in 2007. Overall third quarter revenues increased to $1.4 million compared to $1.2 million in 2007 -- Announced that its partner, Ferring Pharmaceuticals has received additional regulatory approvals in Europe and Australia for use of Antares' needle-free injection devices with Zomacton, its human growth hormone (hGH) product -- Entered into a feasibility agreement with Dr. Reddy's Laboratories, Inc. for the development of an innovative, topically applied product, using Antares' ATD Gel platform, targeting specific receptor sites within the skin -- Our partner Biosante, recently announced that LibiGel for the treatment of Female Sexual Dysfunction is currently in three Phase III trials to support submission and approval of a New Drug Application (NDA) with the FDA. The LibiGel Phase III safety and efficacy trials are being conducted under an FDA approved SPA

Antares Pharma, Inc. (AMEX: AIS) today reported financial and operating results for the third quarter 2008. For the quarter ended September 30, 2008, the Company reported a net loss of $3.2 million, or $0.05 per share, compared to a net loss of $2.6 million, or $0.04 per share for the same period in 2007. For the nine months ended September 30, 2008 the Company reported a net loss of $9.9 million, or $0.15 per share, compared to a net loss of $5.3 million, or $0.09 per share for the same period in 2007. In the first nine months of 2008 the Company used cash of approximately $8.1 million in operating activities principally due to the Companys Phase 3 pivotal trial for Anturol. At September 30, 2008 Antares held approximately $15.8 million in cash and cash equivalents.

The third quarter was a good quarter for Antares; our revenue base from product sales increased, we signed an additional agreement for our ATD gel technology and we achieved additional approvals for our needle-free injection devices. We continue to expect that the sNDA filed for human growth hormone with our needle-free injector could be approved in the fourth quarter of 2008 which will mean additional product revenues in 2009, said Paul K. Wotton, Ph.D., Chief Executive Officer of Antares.

Third Quarter 2008 Financial Results

Product revenue increased in the third quarter of 2008 to $996,000 compared to $904,000 in the prior year. Total revenue increased to $1.4 million for the third quarter of 2008, compared to $1.2 million in 2007. The increase in revenues was primarily due to an increase in product sales to the Companys major European customer, Ferring. Total revenue was $3.9 million for the nine months ended September 30, 2008 compared to $5.9 million for the nine months ended September 30, 2007. The decrease in the first nine months of 2008 compared to 2007 was primarily due to a one-time $1.75 million milestone payment received in the first quarter of 2007 related to an existing license agreement with BioSante Pharmaceuticals, Inc. Product revenue for the nine months ended September 30, 2008 was $2.7 million compared to $2.6 million for the nine months ended September 30, 2007.

Total operating expenses were approximately $3.8 million and $3.4 million for the three months ended September 30, 2008 and 2007, respectively, and were approximately $11.9 million and $9.6 million for the nine months ended September 30, 2008 and 2007, respectively. Operating expenses increased primarily due to the pivotal Phase 3 trial of ANTUROL for the treatment of overactive bladder syndrome (OAB), which we initiated during the second half of 2007. Net loss was approximately $3.2 million and $2.6 million for the quarters ended September 30, 2008 and 2007, respectively, and was approximately $9.9 million and $5.3 million for the nine-month periods ended September 30, 2008 and 2007, respectively. Net cash used in operations increased from $4.0 million for the nine months ended September 30, 2007 to $8.1 million for the comparable period in 2008 as a result of our increased investment in our Anturol clinical study.

About Antares Pharma

Antares Pharma is a product development company committed to improving pharmaceuticals through its patented drug delivery systems. Antares has multiple development partnerships with leading pharmaceutical companies. The Companys products are designed to improve safety and efficacy profiles by minimizing dosing and reducing side effects while enabling improved patient compliance. The Companys lead product candidate, Anturol, an oxybutynin ATD gel for the treatment of OAB (overactive bladder), is currently under evaluation in a pivotal Phase 3 trial. Antares has three validated drug delivery systems: the ATDTM Advanced Transdermal Gel Delivery system; subcutaneous injection technology platforms including VibexTM disposable pressure assisted auto injectors, ValeoTM/Vision® reusable needle-free injectors and disposable multi-use pen injectors and Easy TecTM oral disintegrating tablets (ODT). Two of the systems have generated FDA approved products. Antares Pharma has corporate headquarters in Ewing, New Jersey, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements related to the sNDA filing for human growth hormone being approved in the fourth quarter of 2008 with additional product revenues in 2009, the Companys future financial performance, and other statements which are other than statements of historical facts. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "intends," "plans," anticipates," "believes," "estimates," "predicts," "projects," "potential," "continue," and other similar terminology or the negative of these terms, but their absence does not mean that a particular statement is not forward-looking. Such forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, among others: that the Company may experience difficulties or delays in the initiation, progress or completion of its clinical trials, including the phase 3 trial of Anturol, whether caused by competition, adverse events, investigative site initiation rates, patient enrollment rates, regulatory issues or other factors; that clinical trials may not demonstrate that Anturol is both safe and effective for the treatment of patients with overactive bladder syndrome; that the safety and/or efficacy results of the phase 3 trial of Anturol may not support an application for marketing approval in the United States or any other country; that an application for marketing approval may not be accepted for priority review or at all by the FDA or any other regulatory authority; and that the Company may lack the financial resources and access to capital to fund future clinical trials. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

FINANCIALS FOLLOW

ANTARES PHARMA, INC.

CONSOLIDATED CONDENSED BALANCE SHEETS

(amounts in thousands)

September 30,December 31,
20082007

Assets

(unaudited)

Cash and investments $ 15,828 $ 26,060

Accounts receivable

1,021 487
Patent rights 598 572
Goodwill 1,095 1,095
Other assets 3,733 2,003
Total Assets $ 22,275 $ 30,217
Liabilities and Stockholders Equity
Accounts payable and accrued expenses $ 3,529 $ 2,348
Notes payable 5,304 6,775
Deferred revenue 3,730 3,594
Stockholders equity 9,712 17,500
Total Liabilities and Stockholders Equity $ 22,275 $ 30,217

ANTARES PHARMA, INC.

CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS

(amounts in thousands except share amounts)

(unaudited)

For the Three Months Ended September 30,For the Nine Months Ended September 30,
2008200720082007
Product sales $ 996 $ 904 $ 2,679 $ 2,599
Other revenue 392 327 1,214 3,282
Total Revenue 1,388 1,231 3,893 5,881
Cost of revenue 596 552 1,583 1,587
Gross Profit 792 679 2,310 4,294
Research and development 2,153 1,652 5,911 3,998
Sales, marketing and business development 347 369 1,352 1,186
General and administrative 1,319 1,347 4,642 4,462
Total Operating Expenses 3,819 3,368 11,905 9,646
Operating loss (3,027 ) (2,689 ) (9,595 ) (5,352 )
Other income and expenses (162 ) 78 (352 ) 15
Net loss $ (3,189 ) $ (2,611 ) $ (9,947 ) $ (5,337 )
Basic and diluted net loss per common share $ (0.05 ) $ (0.04 ) $ (0.15 ) $ (0.09 )
Basic and diluted weighted average common shares outstanding

67,980

64,660

66,980

57,608

Contacts:

Antares Pharma, Inc.
Robert F. Apple, 609-359-3020
Chief Financial Officer
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here